Azemiglitazone

Thiazolidinedione class drug

Azemiglitazone
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	201038-24-4
PubChem	9828884
DrugBank
ChemSpider	8004820
KEGG	D02892

Azemiglitazone is a pharmaceutical compound that belongs to the thiazolidinedione class of drugs. It was developed as a potential treatment for type 2 diabetes mellitus, a chronic condition characterized by insulin resistance and high blood sugar levels. Azemiglitazone functions as an agonist of the peroxisome proliferator-activated receptor gamma (PPAR-γ), a type of nuclear receptor that plays a crucial role in the regulation of glucose and lipid metabolism.

Mechanism of Action

Azemiglitazone, like other thiazolidinediones, exerts its effects by activating PPAR-γ. This activation leads to the transcription of genes involved in glucose and lipid metabolism, enhancing insulin sensitivity in peripheral tissues such as adipose tissue, skeletal muscle, and the liver. By improving insulin sensitivity, azemiglitazone helps lower blood glucose levels and can also have beneficial effects on lipid profiles.

Development and Clinical Trials

Azemiglitazone was investigated in clinical trials to assess its efficacy and safety in the management of type 2 diabetes. However, like many drugs in the thiazolidinedione class, its development faced challenges due to concerns about potential side effects, including weight gain, fluid retention, and an increased risk of cardiovascular events. These concerns have led to a cautious approach in the development and approval of new thiazolidinediones.

Pharmacokinetics

The pharmacokinetic profile of azemiglitazone includes its absorption, distribution, metabolism, and excretion. As a thiazolidinedione, it is typically administered orally and undergoes hepatic metabolism. The metabolites are then excreted primarily via the urine. The half-life of azemiglitazone and its metabolites can influence dosing schedules and the duration of its therapeutic effects.

Potential Side Effects

Common side effects associated with thiazolidinediones, including azemiglitazone, may include weight gain, edema, and an increased risk of heart failure. These side effects are thought to be related to the drug's mechanism of action, which involves fluid retention and changes in fat distribution. Long-term use of thiazolidinediones has also been associated with an increased risk of bone fractures.

Current Status

As of the latest updates, azemiglitazone has not been approved for clinical use. The development of new thiazolidinediones continues to be an area of active research, with a focus on improving the safety profile of these drugs while maintaining their efficacy in managing type 2 diabetes.

Related Pages

• Thiazolidinedione
• Type 2 diabetes mellitus
• Peroxisome proliferator-activated receptor
• Insulin resistance